Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 24: The TAVR UNLOAD Trial
Author(s): Nicolas M Van Mieghem Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more

Intervention
Transcatheter Tricuspid Valve Interventions in the TAVR Population
Author(s): Molly Silkowski , Payton Kendsersky , Nicholas Amoroso Added: 1 year ago

Intervention
TCT 24: Pooled Analysis of RHEIA and PARTNER 3
Author(s): Didier Tchétché Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are… View more

Demographic

Intervention
A Rare Case of Quadricuspid Pulmonary Valve
Author(s): Christina A Theochari , Christos Tountas , Nikolaos Tsiamis , et al Added: 1 week ago

Imaging & Diagnostics

Inherited and Congenital Cardiac Conditions
TCT 25: The PREVUE-VALVE Study
Author(s): David J Cohen Added: 7 months ago
TCT 2025 - The PREVUE-VALVE study finds an 8.2% prevalence of moderate or greater valvular heart disease amongst Americans age 65-85, increasing to 18.4% when participants with mild to moderate VHD were included.Dr David J. Cohen (Cardiovascular Research Foundation & St Francis Hospital, US) joins us to discuss findings from the PREVUE-VALVE study, examining age and sex-specific prevalence of… View more

Imaging & Diagnostics

Intervention
CRT 25: The PARTNER 3 Registry
Author(s): S. Chris Malaisrie Added: 1 year ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical… View more

Intervention
LANDMARK: Myval THV Noninferior to Contemporary Valves
Added: 3 months ago Source:  Transcatheter Academy
One-year outcomes from the LANDMARK trial show the Myval transcatheter heart valve (THV) series is noninferior to contemporary THVs for treating symptomatic severe native aortic stenosis.¹ The results demonstrate comparable clinical efficacy and haemodynamic performance at 1 year.MethodologyLANDMARK (NCT04275726) was a prospective, randomised, open-label, noninferiority trial conducted across 31… View more

Demographic

Intervention
TAVI in Pure AR
TAVI in Pure AR

Case Report

Author(s): Deniz Mutlu , Ibrahim Halil Inanc , Ozgecan Piril Zanbak Mutlu , et al Added: 1 year ago

Intervention
Managing LVOT Obstruction in Transcatheter Mitral Replacement with Dr Eleid
Author(s): Mackram F Eleid Added: 7 months ago
Explore advanced strategies for preventing and managing LVOT obstruction in transcatheter mitral valve replacement with Dr Mackram EleidThis presentation, part of Women As One's comprehensive Structural Interventions track, examines of a 90-year-old patient with severe mitral annular calcification, heart failure with preserved ejection fraction, and significant basal septal hypertrophy. Dr Eleid… View more

Intervention
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention